Effect of Probiotics on the Symptomatology of Autism Spectrum Disorder and/or Attention Deficit/Hyperactivity Disorder in Children and Adolescents: Pilot Study.
Meritxell Rojo-Marticella, Victoria Arija, Josefa Canals-Sans
{"title":"Effect of Probiotics on the Symptomatology of Autism Spectrum Disorder and/or Attention Deficit/Hyperactivity Disorder in Children and Adolescents: Pilot Study.","authors":"Meritxell Rojo-Marticella, Victoria Arija, Josefa Canals-Sans","doi":"10.1007/s10802-024-01278-7","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this study is to investigate the impact of using probiotics with strains related to dopamine and gamma-aminobutyric acid production on clinical features of autism spectrum disorder (ASD) and/or attention deficit/hyperactivity disorder (ADHD). This randomized, controlled trial involved 38 children with ADHD and 42 children with ASD, aged 5-16 years, who received probiotics (Lactiplantibacillus plantarum and Levilactobacillus brevis 109/cfu/daily) or placebo for 12 weeks. Parent-reported symptoms were assessed using Conners' 3rd-Ed and the Social Responsiveness Scale Test, 2nd-Ed (SRS-2), and children completed the Conners Continuous Performance Test, 3rd-Ed (CPT 3) or Conners Kiddie CPT, 2nd-Ed (K-CPT 2). Executive functions, quality of life and sleep patterns were also parent-assessed. Intention-to-treat analyses, controlling for sociodemographic and nutritional covariates, revealed no significant inter-group differences in parent-reported or neuropsychological data after the probiotic intervention. However, age-stratified analyses showed improved hyperactivity-impulsivity symptoms in younger children with ASD (Cohen's d = 1.245) and ADHD (Cohen's d = 0.692). Intra-group analyses supported these findings in the aforementioned age and intervention group for both diagnoses. An improvement in impulsivity for children with ASD was also observed in the intra-group analysis of the CPT commissions scores (probiotic: p = 0.001, Cohen's d = -1.216; placebo: p = 0.013, Cohen's d = -0.721). A better comfort score (quality of life) was shown in children with ASD (probiotic: p = 0.010, Cohen's d = 0.722; placebo: p = 0.099, Cohen's d = 0.456). The probiotics used, may improve hyperactivity-impulsivity in children with ASD or/and ADHD and quality of life in children with ASD. Further research is warranted to explore probiotics as an adjunctive therapeutic intervention for NDs.Trial registration: clinicaltrials.gov Identifier: NCT05167110.</p>","PeriodicalId":36218,"journal":{"name":"Research on Child and Adolescent Psychopathology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research on Child and Adolescent Psychopathology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1007/s10802-024-01278-7","RegionNum":2,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of this study is to investigate the impact of using probiotics with strains related to dopamine and gamma-aminobutyric acid production on clinical features of autism spectrum disorder (ASD) and/or attention deficit/hyperactivity disorder (ADHD). This randomized, controlled trial involved 38 children with ADHD and 42 children with ASD, aged 5-16 years, who received probiotics (Lactiplantibacillus plantarum and Levilactobacillus brevis 109/cfu/daily) or placebo for 12 weeks. Parent-reported symptoms were assessed using Conners' 3rd-Ed and the Social Responsiveness Scale Test, 2nd-Ed (SRS-2), and children completed the Conners Continuous Performance Test, 3rd-Ed (CPT 3) or Conners Kiddie CPT, 2nd-Ed (K-CPT 2). Executive functions, quality of life and sleep patterns were also parent-assessed. Intention-to-treat analyses, controlling for sociodemographic and nutritional covariates, revealed no significant inter-group differences in parent-reported or neuropsychological data after the probiotic intervention. However, age-stratified analyses showed improved hyperactivity-impulsivity symptoms in younger children with ASD (Cohen's d = 1.245) and ADHD (Cohen's d = 0.692). Intra-group analyses supported these findings in the aforementioned age and intervention group for both diagnoses. An improvement in impulsivity for children with ASD was also observed in the intra-group analysis of the CPT commissions scores (probiotic: p = 0.001, Cohen's d = -1.216; placebo: p = 0.013, Cohen's d = -0.721). A better comfort score (quality of life) was shown in children with ASD (probiotic: p = 0.010, Cohen's d = 0.722; placebo: p = 0.099, Cohen's d = 0.456). The probiotics used, may improve hyperactivity-impulsivity in children with ASD or/and ADHD and quality of life in children with ASD. Further research is warranted to explore probiotics as an adjunctive therapeutic intervention for NDs.Trial registration: clinicaltrials.gov Identifier: NCT05167110.